Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Block 10-1 Blanchardstown Corporate Park Ballycoolin DUBLIN 15 |
Tel: | 1-212-6988687 |
Website: | https://www.avadel.com |
IR: | See website |
Key People | ||
Gregory J. Divis Chief Executive Officer, Director | Thomas S. McHugh Chief Financial Officer | Richard J. Kim Chief Commercial Officer |
Business Overview |
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs. |
Financial Overview |
For the fiscal year ended 31 December 2023, Avadel Pharmaceuticals PLC (ADR) revenues increased from $0K to $28M. Net loss increased 17% to $160.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, General and administrative increase from $66.8M to $135.5M (expense), Stock-based Compensation in SGA increase from $6.8M to $15.2M (expense). |
Employees: | 154 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,508M as of Dec 31, 2023 |
Annual revenue (TTM): | $27.96M as of Dec 31, 2023 |
EBITDA (TTM): | -$136.08M as of Dec 31, 2023 |
Net annual income (TTM): | -$160.28M as of Dec 31, 2023 |
Free cash flow (TTM): | -$128.51M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 90,576,998 as of Feb 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |